Skip to main navigation
Kyverna Therapeutics Logo
  • Overview
  • News Releases
  • Presentations
  • Governance
    • Governance Overview
    • Board of Directors
    • Leadership Team
    • Committee Composition
  • Financials
    • SEC Filings
  • Stock
    • Stock Quote & Chart
    • Analyst Coverage
  • IR Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR

Investor Relations

Minimum 15 minutes delayed. Source:

global
/investor-relations
Our Mission

Our Mission

To bring life-changing therapeutic benefits to patients living with autoimmune diseases.

Read More
Corporate Presentation

Corporate Presentation

Investor Presentation November 2024

News Releases

Press Releases

November 14, 2024
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024
November 13, 2024
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
October 21, 2024
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
September 18, 2024
Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024
View All News

Investor Contact

drafts InvestorRelations@kyvernatx.com
drafts Media@kyvernatx.com
phone_iphone +1 510.925.2492
© 2024 Kyverna Therapeutics

Social Media

  • LinkedIn opens in new window
  • Glassdoor opens in new window
Search Investors